Feed Hype & Hope updates directly to your favorite news aggregator such as My Yahoo!, NewsGator or FeedDemon.
Published by Zoomedia, Inc.
Zoomedia is a leading communications agency dedicated to increasing our clients' value through insightful and imaginative creative programs for the life sciences industry.
For questions or comments about this site, please contact hypeandhope@zoomedia.com.
©2012 Zoomedia, Inc.
All rights reserved.
Long before the most recent showdown between the U.S. Congress and President George W. Bush over the use of embryonic stem cells, the administration’s intransigence drove proponents...
Imagine a school principal who says he wants to learn how best to incorporate new technologies into the classroom but forbids participation by the most enthusiastic and recently trained...
I never wanted Zach Hall’s job. Now it appears he doesn’t want it anymore either. The former President of the California Institute for Regenerative Medicine (CIRM) resigned earlier...
Though states historically have taken a back seat to the federal government regarding funding biotech research that is no longer the case. States are aggressively using monies and...
Stem cells. We've heard they can cure Parkinson's disease, patch damaged hearts, replace the pancreas, rewire the spinal cord, cure cancer and restore memories lost in the fog of Alzheimer's...
The Stem Cell Research Enhancement Act would allow federal funding for new embryonic stem cell research. It is supported by majorities in the U.S. House of Representatives and the Senate,...
The University of Minnesota has received an $8.6 million contract from the National Institutes of Health (NIH) as part of a federal initiative to accelerate the development of stem-cell therapies for heart, lung and blood diseases and other illnesses. The contract, while small relative to the U's overall body of federally funded research, is almost 8 times larger than a typical NIH grant.
>> Read the StoryBrainStorm Cell Therapeutics Inc. /quotes/comstock/11k!bcli (BCLI) , a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has entered into agreements with three investors with each investing $500,000 for a total of investment of $1.5 million into BrainStorm.
>> Read the StoryVanderbilt University researchers are interested in getting rid of the need for diapers, but not the ones that babies use. The diapers and pads they care about bear names such as Depends or Attends and are worn by adults with urinary incontinence, or loss of bladder control.
>> Read the StoryThe United States government's decision last year to lift restrictions on federally-funded stem cell research has helped the nation's stem-cell researchers concentrate on science, but limitations remain -- even under the new policy, according to George Daley, a Howard Hughes Medical Institute investigator at Children's Hospital Boston.
>> Read the StoryA UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.
>> Read the StoryScientists have created prostate cancer in the laboratory by genetically altering human stem cells. The ability to produce cancer "from scratch" is expected to boost efforts to find agents that combat the disease, which affects around 35,000 men each year in the UK and causes 10,000 deaths. Scientists believe most cancers are driven by "rogue" stem cells - the immature "mother" cells that develop into different kinds of tissue.
>> Read the StoryThe National Institutes of Health is proposing to expand its definition of human embryonic stem cells, enabling the university researchers it finances to work with cells derived from a very early human egg. The proposal will benefit several academic researchers and a company, Advanced Cell Technology, that has filed a request with the Food and Drug Administration to test a treatment for macular degeneration, an eye disease. If approved, it would be among the first clinical tests of embryonic stem cells, which were first discovered in 1998.
>> Read the StoryA new study from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa suggests that stem cells intentionally break their own DNA as a way of regulating tissue development. The study, published in Proceedings of the National Academy of Science (PNAS), could dramatically change how researchers think about tissue development, stem cells and cancer.
>> Read the StoryA software program created by an engineer at the University of Wisconsin-Milwaukee (UWM) can not only predict the types of specialized cells a stem cell will produce, but also foresee the outcome before the stem cell even divides.
>> Read the StoryUmbilical cord blood has proven to save lives. Now scientists might be on the verge of using it to change the lives of children with cerebral palsy. Cord blood stored in huge tanks at the world's largest cord blood bank, which is here in Tucson, has been used to treat nearly 80 diseases, including cancer.
>> Read the StoryA package of six bills to modify Michigan's constitutional amendment that permits embryonic stem cell research appears to be stalled in the Senate because Majority Leader Mike Bishop is concerned the changes could lead to job losses and may not reflect voters' intent in voting for the amendment.
>> Read the StoryBiologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development. Their discovery, which appears in a paper in this week's early online edition of the journal Nature, is a critical first step for the development of safer and more effective stem cell therapies for patients with leukemia, multiple myeloma, anemia and a host of other diseases of the blood or bone marrow.
>> Read the StoryA first head-to-head comparison of human embryonic stem cells with ones grown from skin cells, reported Thursday by biologists, revealed early aging and other abnormalities in the less-controversial alternatives.
>> Read the StoryWhen scientists first created induced pluripotent stem cells (iPS cells) three years ago, they were hailed as a game-changing advance for medicine: Scientists hoped the engineered cells could duplicate the talents of embryonic stem cells, which can develop into any kind of cell in the body, while avoiding the destruction of embryos. However, a new study by one of the leading U.S. cell labs suggests that iPS cells, at least right now, have serious problems keeping them from reaching their potential.
>> Read the StoryToday the Index Value closed at $1.08, up 0.02 -- a gain of 1.89%.
The index value climbed to 0.2967 from 0.2912 with an associated index market cap of $0.891 Billion.
| Company | Ticker | Last | Change | % |
| Advanced Cell Technology | ACTC.OB | $0.12 | -$0.008 | -6.20% |
| Aastrom Biosciences | ASTM | $2.00 | $0.00 | 0.00 |
| AVI Biopharma | AVII | $1.00 | $0.0593 | 6.30% |
| BrainStorm Cell Therapeutics | BCLI.OB | $0.23 | $0.003 | 1.32% |
| CRYO-CELL International | CCEL.OB | $2.20 | -$0.15 | -6.38% |
| Cryo-Save | CRYO.L | $0.00 | $0.00 | 0 |
| Cytori Therapeutics | CYTX | $4.20 | $0.22 | 5.53% |
| Geron Corporation | GERN | $2.08 | $0.055 | 2.72% |
| ThermoGenesis | KOOL | $1.07 | $0.06 | 5.94% |
| MultiCell Technologies | MCET.OB | $0.00 | -$0.0003 | -6.12% |
| NeoStem, Inc. | NBS | $0.67 | $0.0409 | 6.50% |
| Opexa Therapeutics Inc. | OPXA | $0.96 | -$0.039 | -3.92% |
| Osiris Therapeutics, Inc. | OSIR | $5.95 | $0.11 | 1.88% |
| Ortec International, Inc. | OTCI.OB | $0.00 | $0.00 | 0 |
| Stem Cell Thera | SSS.V | $0.05 | $0.00 | 0.00 |
| StemCells | STEM | $1.07 | $0.00 | 0.00 |
Last Close: Feb 4, 2012 17:15:01 PST
View All:
> Stem Cells Events
> Personalized Medicine Events
> Clinical Trials Events